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Abstract
Background
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a decline in
renal function at late disease stage when the majority of functional renal parenchyma is re-
placed by cystic tissue. Thus, kidney function, assessed by estimated glomerular filtration
rate (eGFR) does not well represent disease burden in early disease. Here, we investigated
various urinary markers for tubular injury and their association with disease burden in
ADPKD patients at early disease course.
Methods
ADPKD patients between 18 and 40 years with an eGFR greater or equal to 70 ml per min
per 1.73m2 were eligible for this cross-sectional study. Urinary Neutrophil Gelatinase-Asso-
ciated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), and Uromodulin (UMOD) were
investigated by Enzyme-Linked Immunosorbent Assay. Clara Cell Protein 16 (CC16) was
investigated by Latex Immuno Assay. Cryoscopy was performed to assess urine osmolality
and Urinary Albumin-to-Creatinine Ratio (UACR) was calculated. The association and the
predictive properties of the markers on eGFR and height adjusted total kidney volume
(htTKV) was evaluated using multiple regression analysis, incorporating different control
variables for adjustment. Internal bootstrapping validated the obtained results.
Results
In 139 ADPKD patients (age 31 ±7 years, mean eGFR of 93 ± 19ml per min per 1.73 m2) the
total kidney volume was negatively correlated with eGFR and UMOD and positive associated
with age, UACR, KIM-1 and urine osmolality after adjustment for possible confounders. Urine
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osmolality and htTKV were also associated with eGFR, whereas no association of CC16,
NGAL and UMODwith eGFR or htTKVwas found.
Conclusion
UACR and urinary KIM-1 are independently associated with kidney size but not with renal
function in our study population. Urine osmolality was associated with eGFR and kidney vol-
ume following adjustment for multiple confounders. Despite statistical significance, the clini-
cal value of our results is not yet conceivable. Further studies are needed to evaluate the
property of the aforementioned biomarkers to assess disease state at early ADPKD stage.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inher-
ited kidney diseases. It is characterized by a decline of glomerular filtration rate at advanced
disease stage and a high inter- and intrafamilial variability in age of end stage renal disease
(ESRD) onset, implying a challenge to predict individuals’ disease progression. The develop-
ment and continued accretion of cysts, as the most prominent feature in ADPKD, leads to a
massive enlargement of the kidney and, subsequently, to a loss of its function. So far, no disease
modifying treatment is available, except the recent approval of the vasopressin V2 receptor an-
tagonist Tolvaptan in Japan. Due to glomerular hyperfiltration of the remaining nephrons kid-
ney function stays stable over decades. Thus, traditional markers for kidney function like
serum creatinine and estimated glomerular filtration rate (eGFR) have limited ability to accu-
rately assess disease state and to predict progression in the early course of ADPKD. Increasing
evidence suggests that total kidney volume qualifies as a marker for disease progression in
ADPKD [1]. In fact, the disease state may be reflected more accurately by total kidney volume
and kidney growth rate than renal functional parameters like eGFR or creatinine clearance [2].
Total kidney volume can be accurately assessed by Magnetic Resonance Imaging (MRI). How-
ever MRI derived kidney volume measurements are time and cost intensive, require high tech-
nical expertise and are not routine clinical practice.
Renal cystogenesis in ADPKD is a complex process, characterized by abnormalities in tubular
cell proliferation, fluid secretion, extracellular matrix formation, and cell polarity [3]. The pro-
cess results in an impaired filtration barrier, diminished tubular reabsorption, upregulation of tu-
bular proteins and release of markers by recruited inflammatory cells, which can be detected in
patients’ urine [4]. Such markers should have the property to define the patients’ state in a cer-
tain disease condition, to predict prognosis, and/or to quantify the effect of a pharmacological
approach. Mayeux et al defined type 0 biomarkers (diagnostic biomarkers) reflecting the natural
history and correlating with clinical indices and biomarkers of type 1 (predictive biomarkers)
capturing the effect of an intervention [5,6]. Biomarkers of type 0 that reflect tubular damage
and have been under investigation in various settings of kidney disease are Neutrophil Gelatinase
Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Uromodulin (UMOD), Clara
Cell Protein 16 (CC16) and albuminuria [6]. NGAL has been extensively investigated as a bio-
marker, due to its rapid increase in different settings like acute kidney injury, cardiac surgery,
and kidney transplantation [7–11]. KIM-1 does not occur in human urine under physiological
conditions and has been described as progression marker in kidney disease [2]. UMOD, the
most abundant protein in human urine, regulates tubular function and shows protective proper-
ties against uropathogenic Escherichia coli and nephrolithiasis [12]. Decreasing levels of urinary
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UMOD have been reported in various settings of chronic kidney disease (CKD), like glomerulo-
nephritis, diabetic nephropathy or tubulointerstitial nephropathy [12–15]. Urinary CC16 is con-
sistently associated with defective endocytic uptake by the proximal tubule. CC16 levels are
increased in patients with diabetic and HIV-induced nephropathy, as well as in renal Fanconi
syndrome [16,17]. There is an unmet need to discover new biomarkers that allow an easy and
non-invasive assessment of ADPKD disease state. Here, we investigated the potential properties
of the aforementioned markers for assessing disease state by evaluating their association with
kidney volume and function in patients at early stage of ADPKD.
Methods
Study Subjects
Subjects of the well-described SUISSE ADPKD cohort were eligible for enrolment [18,19].
Male and female patients with proven ADPKD diagnosis, examined by kidney ultrasonogra-
phy, according to Ravine criteria, and a positive family history were eligible when aged between
18 and 40 and presenting with an eGFR greater or equal to 70 ml per min per 1.73m2 as shown
in Table 1 [20]. A proof of a mutation in the PKD1 or PKD2 genes was required for enrolment
of patients without family history (sequencing analysis by Athena Diagnostics Inc., Worcester,
MA, USA). The study was conducted according to the Declaration of Helsinki and Good Clini-
cal Practice Guidelines and was approved by the local ethical board. All patients provided writ-
ten informed consent.
Study Procedure
Subjects were invited to the outpatient clinic at the Division of Nephrology (University Hospi-
tal Zurich). At study visit the medical history was obtained, including medication and ADPKD
related complications. Blood pressure measurement was done in duplicate at each arm after 5
minutes of rest in sitting position using an oscillometric blood pressure device (Boso-Medicus,
Jungingen, Germany). Hypertension was defined as systolic blood pressure above 140 mmHg
and/or diastolic blood pressure above 90 mmHg or antihypertensive treatment. Fasting spot
urine samples were collected after voiding the first urine of the day to measure creatinine beside
the potential biomarkers. Blood samples were centrifuged and aliquoted, according to a stan-
dardized process, to obtain serum. Serum and spot urine aliquots were stored at—80°C before
analysis.
Laboratory Analysis
At study visit, serum creatinine was measured according to modified Jaffé method traceable to
an isotope-dilution mass spectroscopy reference. Estimated GFR was calculated by applying
Table 1. Eligibility criteria19.
• Age 18 to 40
• GFR  70 ml per min per 1.73m2 (Cockcroft-Gault formula)
■ Clinical diagnosis of ADPKD based on kidney imaging (modiﬁed Ravine criteria) and family history
■ Positive family history for ADPKD
 patients < 30 years:  2 cysts in either kidney
 patients  30 years:  2 cysts in each kidney
• Negative family history for ADPKD cystic kidney disease by sonography: proof of a mutation in the PKD1
or PKD2 gene
• Patient provided written informed consent
doi:10.1371/journal.pone.0123555.t001
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the CKD-EPI equation [21]. NGAL (BioPorto Diagnostics A/S, Hellerup, Denmark) and KIM-1
(R&D Systems Inc., Abingdon, UK) were analyzed using commercially available Enzyme-linked
Immunosorbent Assays (ELISA) according to manufacturers protocol. UMOD was analyzed by
a well established ELISA based on a sheep anti-human uromodulin antibody (K90071C; Meridi-
an Life Science, Memphis, TN) as the capture antibody, a mouse monoclonal anti-human
Tamm–Horsfall protein antibody (CL 1032A; Cedarlane Laboratories, Burlington, NC) as the
primary antibody, and a goat anti-mouse IgG (H+L) horseradish peroxidase–conjugated protein
(172.1011; Bio-Rad Laboratories, Inc., Hercules, CA) as a secondary antibody. Human uromo-
dulin (AG 733, stock solution: 100 μg/ml; EMDMillipore, Temecula, CA) was used to establish
the standard curve [22]. CC16 was analyzed with continuous flow Latex Immuno Assay (LIA)
and an assayable concentration of CC16 between 0.3 and 40 μg/L [23]. Albuminuria was assessed
using Synchron Systems for Microalbumin (Beckman Coulter Inc., Brea, California, USA). The
urinary albumin-to-creatinine ratio (UACR) was calculated as follows: Albumin (mg/dl) x 1/cre-
atinine (mg/dl) x 1000 μg/mg. The analysis of urine osmolality was performed by cryoscopy
using a freezing point depression Advanced 2020-BIOMulti-Sample Osmometer (Advanced In-
struments Inc., Norwood, Massachusetts, USA). All samples were handled in a uniform way and
underwent no freeze-thaw cycle before analyzed in duplicate.
Magnetic Resonance Imaging
Patients underwent magnetic kidney imaging without contrast media according to a standard-
ized imaging protocol. The imaging was performed using a Signa Excite HDx system (GE
Healthcare, Waukesha, WI, USA) and signal perception was obtained with an eight-channel
antero-posterior-phased array surface coil. Trans-axial sequences consisted of two breathhold
T1-weighted fast-spoiled gradient echo sequences with 3 and 4 mm slice thicknesses. Additional-
ly, a trans-axial T2-weighted fast spin echo sequence with respiratory triggering was performed
with 3 mm slice thickness. Right and left kidney volumes were measured and calculated using
the Advantage Windows workstation (4.4 GE Healthcare, Buc, France). Total kidney volume
(TKV) was calculated by adding the volume of the left and right kidney. Measurements of renal
volume were done in a blinded way by two trained and independent observers. The renal hilum
and the vessels were excluded from renal volume calculation. Variability was calculated as con-
cordance correlation coefficients (95% CI) and were 1.000 (0.999–1.000) for intraobserver and
0.996 (0.995–0.999) for interobserver correlations [24].
Statistical Analysis
SAS 9.4 was used for data analysis. A plausibility check of the data preceded the statistical analy-
sis. Univariate methods were used to characterize study population. Values are given in means
with standard deviation. TKV and height adjusted kidney volume (htTKV) are reported as medi-
an because of a skewed distribution of these parameters. Median is reported with interquartile
range.
Spearman’s correlation coefficient (r) was calculated to describe the correlation between
biomarkers and eGFR and htTKV. To calculate r, reflecting the relative variance part, all values
of the parameters are sorted and given a rank [25]. A positive r indicates a concordant associa-
tion, whereas a negative r stands for an opposing association.
The association of biomarkers with eGFR and htTKV was evaluated by incorporating dif-
ferent control variables for adjustment and following a multiple linear regression approach.
A stratum specific correlation analysis was performed for binary and ordinal variables. Mul-
tiple regression analysis gives information about importance and size effect of the predictors
on the response variable, and about the interaction between predictors. Prerequisites, like the
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independence of predictors to each other, were evaluated and fulfilled. The models were de-
termined with scatterplots and correlation analysis to verify linearity between outcome vari-
able and predictors. Subsequently the regression equation was formed. Adjusted R2 and p-
value were calculated as statistic measures. R2, the coefficient of determination, reflects the
proportion response variation that is explained by the predictors [26]. Predictor variables
were selected according to logical considerations and added sequentially to the models. The
models were compared using the Akaike information criterion (AIC). The AIC is based on
the likelihood and determines which model is more likely to be correct and comes closer to
the “truth” [27]. The smaller the AIC value the more realistic the model is, assuming, that a
robust model predicts the data well containing preferably a low number of predictors meet-
ing the requirement for parsimony and avoiding overfitting [28]. Bootstrapping was applied
to estimate the 2.5th and 97.5th percentile confidence intervals for each model. Our dataset
was used as a pool from which 500 new datasets of the same size were randomly drawn with
replacement to internally validate our model results.
Results
Demographics
Between April 2006 and April 2011 139 ADPKD patients were consecutively enrolled in the
study. The mean age was 31±7 years and 85 (61%) patients were male. Hypertension was pres-
ent in 82 (78%) patients, and 80 (58%) patients received antihypertensive medication. Among
those, 50 patients received angiotensin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs), 16 received diuretics and 14 were treated with calcium antagonists.
The mean eGFR was 93±19 ml per min per 1.73 m2 and 74 (53%) of the patients had an eGFR
greater than 90 ml per min per 1.73 m2. The median TKV was 860 cm3 (IQR, 568 to 1191 cm3)
and 52 (37%) patients had a TKV greater than 1000 cm3. The median htTKV was 455 cm3
(IQR, 17 to 669 cm3). The mean body mass index (BMI) was 24±4 kg per m2, 5 (4%) patients
had a BMI lower than 18.5 kg per m2 and 53 (38%) patients a BMI above 25 kg per m2
(Table 2).
Analysis of biomarker
The results of the urinary parameters osmolality, NGAL, KIM-1, UMOD, UACR and CC16
were tabulated for the complete cohort and stratified for eGFR and TKV (Table 3). Osmolality
was measured in 139 spot urine samples. All other potential biomarkers were measured in 132
samples. The median urinary osmolality was 364 mosmol per kg H2O (IQR, 257 to 533 mos-
mol per kg H2O). The median values were 9.8 μg per g creatinine (IQR, 5.3 to 23.7 μg per g cre-
atinine) for NGAL, 274.6 ng per g creatinine (IQR, 131.3 to 457.3 ng per g creatinine) for KIM-
1, and 16.3 mg per g creatinine (IQR, 10.2 to 26.7 mg per g creatinine) for UMOD. In the
whole cohort, UACR was 14.0 mg per g creatinine (IQR, 8.4 to 23.1 mg per g creatinine) and
the median for CC16 was 2.8 μg per l per g creatinine (IQR, 2.0 to 6.2 μg per l per g creatinine).
The median of KIM-1 was significantly higher among patients with TKV above 1000 cm3 than
among patients with TKV lower or equal 1000 cm3. Osmolality, NGAL, UMOD, UACR and
CC16 were similar among patients with an eGFR above 90 ml per min per 1.73m2 and less or
equal 90 ml per min per 1.73m2.
Correlation of biomarker with indices of disease progression
Table 4 shows the correlation of biomarkers with eGFR and TKV. Estimated GFR was negatively
correlated with TKV (r = -0.44508, p<0.05), htTKV (r = 0.45531, p<0.05), age (r = -0.51026,
Urinary Biomarkers in Early ADPKD
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p<0.05) and UACR (r = -0.20042, p<0.05). TKV was negatively correlated with eGFR (r =
-0.44508, p<0.05) and UMOD (r = -0.22771 p<0.05) and positively correlated with age
(r = 0.22493, p<0.05), urinary albumin (r = 0.25524, p<0.05), osmolality (r = 0.1949, p<0.05)
and KIM-1 (r = 0.32129, p<0.05) (Table 4). Biomarker distribution is shown in Figs 1 and 2.
Regression analysis for htTKV and eGFR as outcome parameter
Simple and multiple linear regression analysis were applied to delineate the independent asso-
ciations of urinary biomarkers with eGFR and htTKV. Kidney volume is affected by a number
of a priori known biological factors, e.g. age, gender, and glomerular filtration rate. Predictive
variables were chosen in a predefined step-wise approach: In model 1 (Table 5) eGFR (β =
-0.45968, p<.0001) was selected as a predictor; the term eGFR captures race, age and gender.
The prognostic power of eGFR to predict htTKV is 20.6% (R2 = 0.2055) with an AIC of -199.6.
Bootstrapping revealed a percentile confidence interval of 0.0987 and 0.3374.
Table 2. Characteristics of study cohort.
ADPKD
n = 139
Age—years 31±7
Sex—no. (%)
Female 54 (39)
Male 85 (61)
Body mass index—kg per m2 24±4
BMI <18.5 5 (4)
BMI 18.5–25 81 (58)
BMI >25 53 (38)
eGFR—ml per min per 1.73m2 93±19
CKD stage 1 74 (53)
CKD stage 2 61 (44)
CKD stage 3 4 (3)
TKV—cm3 860 (568 to 1191)
htTKV—cm3 per m 455 (317 to 669)
Hypertension—no. (%)*
Yes 82 (78)
No 23 (22)
Blood pressure—mmHg
Systolic 131±16
Diastolic 83±11
Antihypertensive Medication—no. (%)
ACE / ARB 50 (36)
Calcium antagonist 14 (10)
Diuretics 16 (12)
Abbreviations: eGFR—estimated glomerular ﬁltration rate. TKV—total kidney volume, htTKV—height
adjusted total kidney volume, ACE—angiontensin converting enzyme, ARB—angiotensin II receptor
blocker. Values are means ± standard deviation and numbers (percentage), TKV and htTKV are reported
as median (interquartile range)
*total number of observations = 105
doi:10.1371/journal.pone.0123555.t002
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The selection of osmolality and UACR to model 1 as independent variables increased the R2
to 0.3373 (percentile CI, 0.2306–0.4755), and the AIC to -210.7 (Table 6; Model 2). An increase
of UACR (b = 0.20465, p<.0001) and urine osmolality (b = 0.32114, p<.0001) is independently
of renal function, race, age, and gender associated with an increase in htTKV. All predictors of
model 2 are independently predictors of htTKV at an alpha level of 0.1%. Estimated GFR has
the most predictive power of all 3 variables in this model (β = -0.42435). The standardized esti-
mate β was calculated to evaluate the predictors independently of their transformation and
their level of measurement.
Adjusted R2 of model 3 was 0.3366 after selection of KIM-1, NGAL, UMOD, CC16 to
eGFR, osmolality and UACR (Table 7). A percentile confidence interval of 0.2866 to 0.5278
was obtained in bootstrap validation. Out of the seven aforementioned variables, eGFR, osmo-
lality, UACR and KIM-1 are major factors to predict htTKV. In model 3, the variable UACR is
the second largest predictor variable with a β of 0.30403. Osmolality had a β of 0.21408, and
KIM-1 a β of 0.18993. NGAL, UMOD and CC16 had low β-values and were minor determi-
nants in the prognosis of htTKV. In model 3 osmolality, UACR and KIM-1 are positively cor-
related with kidney volume. The AIC of model 3 was -209.9. The additional selection of KIM-
1, NGAL, UMOD and CC16 did not increase R2 and did not change AIC.
Subsequently different models were established to predict eGFR. In model 1 (Table 8)
htTKV and osmolality were added on priory knowledge to predict eGFR. Both variables were
independently associated with eGFR, and htTKV (β = -0.49803) had a larger association with
Table 3. Biomarker Analysis.
n Complete Cohort eGFR >90 ml per min
per 1.73m2
eGFR 90 ml per min
per 1.73m2
TKV 1000 cm3 TKV >1000 cm3
Osmolality—mosmol per
kg H2O
139 364 (257 to 533) 377 (266 to 534) 360 (243 to 506) 330 (236 to 497) 417 (332 to 547)
NGAL— μg per gcreatinine 132 9.8 (5.3 to 23.7) 8.7 (4.7 to 22.8) 11.3 (5.8 to 24.3) 12.5 (5.3 to 24.3) 9.0 (5.3 to 21.3)
KIM-1—ng per gcreatinine 132 274.6 (131.3 to
457.3)
272.0 (113.9 to 448.8) 274.6 (161.3 to 479.9) 211.6 (106.4 to
362.5)
391.3 (196.1 to
581.0)*
UMOD—mg per gcreatinine 132 16.3 (10.2 to 26.7) 18.1 (10.9 to 29.8) 14.8 (9.1 to 25.6) 19.4 (10.7 to
28.5)
13.6 (8.3 to 21.6)
UACR—mg per gcreatinine 132 14.0 (8.4 to 23.1) 11.6 (6.9 to 21.8) 15.4 (9.9 to 27.2) 12.0 (7.7 to 21.3) 15.2 (10.4 to 31.1)
CC16 – μg per l per
gcreatinine
132 2.8 (2.0 to 6.2) 3.0 (2.0 to 5.9) 2.6 (2.0 to 6.2) 2.6 (2.0 to 4.8) 3.2 (1.7 to 8.9)
Abbreviations: NGAL—Neutrophil Gelatinase Associated Lipocalin, KIM-1—Kidney Injury Molecule-1, UMOD—Uromodulin, UACR—Urinary Albumin-to-
Creatinine Ratio, CC16—Clara Cell Protein 16. Values are reported as median (interquartile range)
* p < 0.05
doi:10.1371/journal.pone.0123555.t003
Table 4. Spearman Correlation Coefficient r.
eGFR TKV htTKV Age NGAL OSMOL KIM-1 UMOD UACR CC16
eGFR 1 -0.44508* -0.45531* -0.51026* -0.06826 0.13563 -0.0867 0.14841 -0.20042* 0.01184
TKV -0.44508* 1 0.99389* 0.22493* -0.0254 0.1949* 0.32129* -0.22771* 0.25524* 0.12924
Abbreviations: eGFR—estimated glomerular ﬁltration rate, TKV—total kidney volume, htTKV—height adjusted total kidney volume, NGAL—Neutrophil
Gelatinase Associated Lipocalin, OSMOL—Osmolality, UMOD—Uromodulin, KIM-1—Kidney Injury Molecule-1, UACR—Urinary Albumin-Creatinine-Ratio,
CC16—Clara Cell Protein 16.
* p < 0.05
doi:10.1371/journal.pone.0123555.t004
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eGFR compared with osmolality (β = 0.22936). The adjusted R2 for this model is 0.2515 (per-
centile CI, 0.1588–0.3809) and thus approximately 25% of eGFR variation is explained by
htTKV and osmolality.
In model 2 (Table 9) the predicting parameters htTKV, osmolality and UACR account for
22.09% of eGFR variation with an adjusted R2 of 0.2209. A percentile confidence interval of
0.1319 to 0.3738 was obtained in bootstrap validation. The predictor htTKV has the largest im-
pact on the outcome in this model (β = -0.48736) and osmolality showed the second largest
value for standardized estimate (β = 0.21857). UACR has a comparably low β.
In model 3 (Table 10) the parameters htTKV, osmolality, UACR, NGAL, KIM-1, UMOD
and CC16 were entered. Height adjusted total kidney volume (β = -0.47261; p<.0001) and os-
molality (β = -0.27024; p = 0.006) were independently associated with changes of eGFR. The
Fig 1. Estimated glomerular filtration rate (eGFR) and parameter distribution.
doi:10.1371/journal.pone.0123555.g001
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Fig 2. Total kidney volume (TKV) and parameter distribution.
doi:10.1371/journal.pone.0123555.g002
Table 5. Simple linear regression height adjusted total kidney volume (transformed to log htTKV) Model 1.
variable Parameter estimate b p Standardized estimate β Standard Error Adjusted R2 AIC
Intercept 2.20103 <.0001 0 0.1145 0.2055 -199.6
eGFR1 —ml per min per 1.73m2 -0.00007127 <.0001 -0.45968 0.00001181
1square root transformed
doi:10.1371/journal.pone.0123555.t005
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additional selection of NGAL, KIM-1, UMOD and CC16 resulted in a stable R2 and AIC. Boot-
strapping revealed a percentile confidence interval of 0.1674 to 0.4153.
Discussion
The cystogenesis in ADPKD replaces functional renal parenchyma and leads to a loss of kidney
function during patients’ lifespan. Since GFR, a traditional parameter of renal function, is not
able to accurately assess disease state in the early disease course, the interest in establishing uri-
nary biomarkers for ADPKD has increased. In this cross-sectional study, we investigated the
potential biomarkers osmolality, UACR, NGAL, UMOD, CC16, KIM-1 at a single time point
in spot urine samples of 139 ADPKD patients with preserved renal function. Robust statistical
approach demonstrated that urinary KIM-1, urinary osmolality and UACR are independently
associated with kidney volume in our cohort of ADPKD patients.
An increase in urinary KIM-1, that is only fractionally expressed under physiological condi-
tions, reflects tubular damage in the proximal S3 tubule segment as shown in acute and chronic
kidney injury [29]. In our study, KIM-1 showed the strongest correlation with TKV. Multiple
regression analysis revealed an independent correlation of KIM-1 with kidney volume, after
adjustment for eGFR, osmolality, UACR, NGAL, UMOD, and CC16. In contrast, KIM-1 was
not associated with renal function in multiple regression analysis adjusted for renal volume, os-
molality, UACR, NGAL, KIM-1, UMOD, and CC16. KIM-1 expression was found in murine
polycystic kidneys but not in wild type mice, driving the hypothesis that ADPKD patients may
display higher urinary KIM-1 excretion [29]. KIM-1 has been identified as novel ciliary mole-
cule. By interacting with the PKD2 Protein Transient Receptor Potential Polycystic 2, KIM-1
may be involved in cellular response to changes in extracellular fluid flow detected by the
Table 6. Multiple linear regression height adjusted total kidney volume (transformed to log htTKV) Model 2.
variable Parameter estimate b p Standardized estimate β Standard Error Adjusted R2 AIC
Intercept -0.29424 0.5704 0 0.51711 0.3373 -210.7
eGFR1 – ml per min per 1.73m2 -0.00006612 <.0001 -0.42435 0.00001149
Osmolality2 – mosmol per kg H2O 0.32114 <.0001 0.30774 0.07825
UACR2 – mg per gcreatinine 0.20465 <.0001 0.31058 0.04985
1 square root transformed
2 log transformed
doi:10.1371/journal.pone.0123555.t006
Table 7. Multiple linear regression height adjusted total kidney volume (transformed to log htTKV) Model 3.
variable Parameter estimate b p Standardized estimate β Standard Error Adjusted R2 AIC
Intercept 0.00847 0.9895 0 0.64145 0.3366 -209.9
eGFR1 —ml per min per1.73m2 -0.00006259 <.0001 -0.40173 0.00001166
Osmolality2 —mosmol per kg H2O 0.2234 0.0186 0.21408 0.09366
UACR2 —mg per gcreatinine 0.20033 0.001 0.30403 0.05951
KIM-12 —ng per gcreatinine 0.09432 0.0191 0.18993 0.0475
NGAL2 – μg per gcreatinine -0.05253 0.2709 -0.09574 0.0397
UMOD2 —mg per gcreatinine -0.04606 0.4653 -0.06085 0.06289
CC162 – μg per l per gcreatinine -0.00504 0.9212 -0.00794 0.05087
1 square root transformed
2 log transformed
doi:10.1371/journal.pone.0123555.t007
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cilium [30]. To our knowledge urinary KIM-1 levels in ADPKD has only been reported once.
In a study of Meijer et al increased KIM-1 levels in 24h urine samples of ADPKD patients were
associated with total kidney volume, adjusted for age, gender and albuminuria compared with
healthy volunteers [2]. In our study, KIM-1 was associated with TKV whereas renal function
that is stable at early disease stage was not associated with KIM-1. Given the limited available
data of KIM-1 in APDKD patients, it is not possible to draw a conclusion about the property of
KIM-1 as biomarker in early ADPKD.
A defect in osmoregulation has been shown in animal models of ADPKD as well as in pa-
tients [31–33]. The impaired capacity of urine concentration is an early manifestation and can
be observed in children [33,34]. With our study we confirm the independent association of os-
molality and TKV as shown by Ho et al [33]. Following multiple adjustment, urine osmolality
is independently associated with kidney volume and function in our cohort. Hence, the assess-
ment of spot urine osmolality may add further information for disease state assessment in
ADPKD patients at early disease stage.
Albuminuria is known as marker for kidney damage for years. Urinary albumin excretion is
routinely assessed in the diagnosis of renal injury, due its urinary appearance prior to GFR de-
cline in different renal diseases. Albuminuria is associated with CKD progression, decreasing
eGFR, increasing TKV, myocardial infarction and mortality [24,35–39]. In our study, UACR
predicts the variation in htTKV but did not qualify as predictor for kidney function.
KIM-1, urine osmolality and UACR are independently associated with disease state in our
study, but no association of NGAL, UMOD and CC16 with kidney volume and function at
early ADPKD state was found. NGAL has been extensively studied as biomarker in acute kid-
ney injury, but only limited data is available reporting NGAL levels in ADPKD [7–11,40]. Boli-
gano et al reported markedly increased urinary NGAL levels in ADPKD patients at late disease
state (eGFR 59 ± 38 ml per minute, Cockcroft-Gault formula) compared with healthy volun-
teers [41]. Parikh and colleagues investigated serum and urinary NGAL levels over a three year
period in participants of the CRISP study, with kidney function comparable to our investigated
cohort (creatinine clearance>70 mls/min). The majority of subjects showed normal to low
baseline urinary NGAL levels. Even so the levels increased during the study period with a drop
at 2nd and third year follow up, no association of NGAL quartiles with kidney volume and
Table 8. Multiple linear regression estimated glomerular filtration rate (square root transformed eGFR) Model 1.
variable Parameter estimate b p Standardized estimate β Standard Error Adjusted R2 AIC
Intercept 4899.70827 0.1014 0 2970.99215 0.2515 2214.2
htTKV1 – cm3 per m -3212.08387 <.0001 -0.49803 483.52856
Osmolality1 – mosmol per kg H2O 1549.70316 0.0027 0.22936 506.54097
1 log transformed
doi:10.1371/journal.pone.0123555.t008
Table 9. Multiple linear regression estimated glomerular filtration rate (transformed to square root eGFR) Model 2.
Variable Parameter estimate b p Standardized estimate β Standard Error Adjusted R2 AIC
Intercept 4899.8604 0.1681 0 3534.68607 0.2209 2104.3
htTKV1 – cm3 per m -3127.98641 <.0001 -0.48736 543.58333
Osmolality1 – mosmol per kg H2O 1463.87536 0.0098 0.21857 557.90345
UACR1 – mg per gcreatinine 100.97551 0.7824 0.02388 364.80352
1 log transformed
doi:10.1371/journal.pone.0123555.t009
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function were seen. Furthermore they showed highly elevated NGAL levels in cystic fluid in
ADPKD patients compared to urine and serum values of healthy and of patients with AKI. The
discrepancy of NGAL levels in urine and in cyst fluid may be attributable to a missing commu-
nication between tubules and detaching cysts in ADPKD [40]. In summary, NGAL levels may
increase only in advanced disease and NGAL is not suitable to predict outcome at early stage
when renal function is maintained.
To our knowledge, UMOD and CC16 levels have not been reported in ADPKD so far. In
our study, no association of UMOD and CC16 with renal function and kidney volume was ob-
served. Decreasing levels of urinary UMOD, which is the most abundant protein in human
urine, have been reported in various settings of CKD [12–15]. Since the absolute values for uri-
nary UMOD in our cohort are comparable with the ones reported in various cohorts, one
could speculate that UMOD excretion decline starts in later stage of ADPKD [42,43]. CC16 is
secreted by bronchial Clara cells and, after filtration, reabsorbed by receptor-mediated endocy-
tosis in the early segments of the proximal tubule [17]. Hence, all disorders associated with de-
fective proximal tubule endocytosis lead to the urinary loss of CC16 [44]. The described lack of
association of CC16 with kidney volume in contrast to KIM-1 probably reflects the functional
segmentation of the proximal tubule, with endocytosis being particularly active in the S1-S2
segments whereas secretory pathways take place in the S3 segment [45].
Our cross-sectional study has to be interpreted in the context of the study setting. We report
independent association between biomarkers and outcome of a relatively high number of
young ADPKD patients. We are not able to conclude about causal relationships between uri-
nary biomarkers and outcome parameter. The parameters were only investigated at a single
time point and we are not able to infer whether or not biomarker excretion precedes decrease
in renal function and increase in kidney volume. Furthermore, our results are based on a single
centre in the absence of comparative groups of healthy volunteers or other CKD patients, mak-
ing it impossible to assess the specificity of our findings for ADPKD. To partially account for
the study limitations, we performed internal validation of our data set by bootstrapping. De-
spite adjustment for multiple confounders of our predictive models, we are not able to fully
eliminate the potential for bias and confounding. We followed a robust and reliable statistical
approach to investigate the diagnostic properties of different urinary biomarkers in a large co-
hort of ADPKD patients in early disease stage. Based on our results we hypothesize that osmo-
lality, UACR and KIM-1 may have the property to assess disease state at early ADPKD disease
course, whereas NGAL, UMOD and CC16 seem not to qualify as biomarkers. Further studies
are necessary to define the biomarker properties of the investigated parameter to predict dis-
ease burden in ADPKD.
Table 10. Multiple lineare regression estimated glomerular filtration rate (transformed to square root eGFR) Model 3.
Variable Parameter estimate b p Standardized estimate β Standard Error Adjusted R2 AIC
Intercept 170.01158 0.9697 0 4465.37589 0.2195 2108.4
htTKV1 – cm3 per m -3333.33092 <.0001 -0.47261 564.97273
Osmolality1 – mosmol per kg H2O 1809.95369 0.006 0.27024 646.61622
UACR1 – mg per gcreatinine 42.27981 0.9224 0.01 432.9461
NGAL1– μg per gcreatinine -136.7632 0.6812 -0.03884 332.06115
KIM-11 – ng per gcreatinine 185.45311 0.5123 0.05818 282.16858
UMOD1 – mg per gcreatinine 798.52678 0.0675 0.16434 432.84451
CC161 – μg per l per gcreatinine -138.45145 0.6963 -0.03397 353.90411
1 log transformed
doi:10.1371/journal.pone.0123555.t010
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